Latest Ratios: P/E Ratio -4.2x · EV/EBITDA N/A · ROE -110.2%. (2004–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $41M | $60M | $11M | $403M | $438M | $204M | $4.2B | — | — | — |
| Enterprise Value | $36M | $55M | $11M | $403M | $436M | $206M | $4.2B | — | — | — |
| P/E Ratio → | -4.16 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 30.16 | 44.27 | — | — | — | 2725.33 | 135427.19 | — | — | — |
| P/B Ratio | 2.79 | 3.40 | 2.74 | 93.38 | 98.33 | 86.96 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 40.31 | — | — | — | 2750.70 | 135488.47 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.7% | 86.7% | — | — | — | 100.0% | -3034.5% | — | — | — |
| Operating Margin | -956.9% | -956.9% | — | — | — | -18727.9% | -22305.5% | — | — | — |
| Net Profit Margin | -874.3% | -874.3% | — | — | — | -17932.4% | -29765.9% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -110.2% | -110.2% | -261.1% | -485.1% | -1104.5% | -572.2% | — | -14.2% | — | — |
| ROA | -82.9% | -82.9% | -125.8% | -266.1% | -511.9% | -380.7% | -3879.5% | -1.4% | -343.2% | 5642.7% |
| ROIC | -114.5% | -114.5% | -171.3% | -474.9% | -735.8% | -2118.9% | — | — | — | — |
| ROCE | -116.1% | -116.1% | -212.2% | -397.0% | -701.9% | -351.1% | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.36 | 0.28 | 0.46 | 1.74 | — | 9.73 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.89 | — | 0.04 |
| Net Debt / Equity | — | -0.30 | 0.22 | -0.06 | -0.39 | 0.81 | — | 9.70 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 0.89 | — | 0.04 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | 0.06 |
| Interest Coverage | -18.11 | -18.11 | -26.29 | -196.49 | -171.03 | -70.87 | -60.79 | — | — | — |
Net cash position: cash ($6M) exceeds total debt ($268875)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.16 | 4.16 | 0.23 | 0.59 | 1.81 | 0.79 | 0.04 | 0.00 | 0.22 | 0.00 |
| Quick Ratio | 4.16 | 4.16 | 0.23 | 0.59 | 1.81 | 0.79 | 0.04 | 0.00 | 0.22 | 0.00 |
| Cash Ratio | 3.59 | 3.59 | 0.12 | 0.49 | 1.75 | 0.79 | 0.04 | 0.00 | 0.22 | 0.00 |
| Asset Turnover | — | 0.07 | — | — | — | 0.01 | 0.10 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 1.97 | — | — | — | — | 258.51 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — | — |
| Shares Outstanding | — | $4M | $2M | $26M | $14M | $1M | $20M | $11M | $1863 | $1863 |
Imminent liquidity and dilution
According to recent market data, COEP trades at a price-to-sales ratio of 32.07, which appears to reflect an aggressive valuation premium that is disconnected from current revenue generation and relies entirely on the successful clinical validation of the GEAR platform rather than existing commercial fundamentals.
The elevated P/S multiple suggests that investors are pricing the company as a high-growth biotech entity, yet the lack of a forward P/E or meaningful EBITDA indicates that this valuation is purely speculative. Analysts should note that such multiples are highly sensitive to clinical trial news, and any delay in the CD38-GEAR-NK program could lead to a rapid compression of this valuation.
Based on reported financial figures, Coeptis has consistently generated negative returns on invested capital, with ROIC plummeting to -63.2% in 2023Q4, indicating that the company is currently destroying shareholder value as it attempts to fund its early-stage research and development pipeline through external capital.
The persistent negative ROIC trend highlights the structural difficulty of achieving efficiency in a pre-commercial biotech model where R&D costs are inelastic. Investors should monitor whether the company can eventually pivot toward a partnership-based model that reduces the burden on its own capital base, as current trends suggest a continued reliance on dilutive financing.
As reported in financial statements, the company's cash conversion cycle remains highly erratic, with days payable outstanding reaching as high as 2382 in 2025Q1, suggesting that Coeptis is managing its liquidity by significantly delaying payments to vendors rather than through operational efficiency or optimized working capital management.
The extreme fluctuations in DPO indicate that the company's cash management is reactive to its limited liquidity position rather than strategic. This reliance on extended payment terms may pose operational risks if suppliers tighten credit, potentially jeopardizing the continuity of clinical trial activities.
Based on the provided quarterly data, the current ratio has swung from a low of 0.23 in 2024Q4 to 3.25 in 2026Q1, which indicates that the company's ability to meet short-term obligations is entirely dependent on the timing of capital raises rather than stable internal cash generation.
The volatility in the current ratio underscores the company's vulnerability to liquidity shocks. Without a consistent source of revenue, the company remains in a state of perpetual capital dependency, which warrants close investigation by analysts regarding the timing and terms of future equity or debt issuances.
Investors frequently misapply the price-to-earnings ratio to Coeptis, which obscures the company's true financial health by focusing on accounting losses that are expected in a pre-revenue biotech firm, rather than evaluating the cash runway and the probability-weighted value of its clinical pipeline assets.
Using P/E or EV/EBITDA for a company with negative margins and no commercial product is fundamentally flawed, as these metrics fail to capture the value of the GEAR platform's intellectual property. A more appropriate approach would involve a risk-adjusted net present value analysis of the clinical pipeline, which accounts for the high probability of failure inherent in early-stage biotechnology.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying COEP stock.
Coeptis Therapeutics, Inc.'s current P/E ratio is -4.2x. This places it at the 50th percentile of its historical range.
Coeptis Therapeutics, Inc.'s return on equity (ROE) is -110.2%. The historical average is -217.7%.
Based on historical data, Coeptis Therapeutics, Inc. is trading at a P/E of -4.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Coeptis Therapeutics, Inc. has 86.7% gross margin and -956.9% operating margin.